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INTRODUCTION
A common cause of brain injury during the perinatal period
is hypoxic-ischemic injury, which frequently results in the
chronic handicapping conditions such as cerebral palsy, mental
retardation, learning disability, and epilepsy (1). Predicting
the outcome of neonates with hypoxic-ischemic injury, how-
ever, is difficult, because some methods that predict outcome
have not reliably or consistently predicted long term neuro-
logic outcomes. Recently, 1H-magnetic resonance spectros-
copy (MRS) has been used as a quantitative noninvasive tool
to assess the biomechanical changes associated with central
nervous system injury. 1H-MRS, which provides objective
extent of hypoxic-ischemic insults, enhances predictability
and provides a method to assess treatment effect (2-5). 
The exact mechanism by which hypoxic-ischemic brain
injury occurs in neonates is not clear, although increasing
evidences indicate that hypoxic-ischemic induced neuronal
death includes both necrosis and apoptosis. Necrosis may
predominate in acute damage, whereas apoptotic injury may
take time to develop. Therefore, blocking the apoptotic cas-
cade may prolong the therapeutic window after hypoxic-ische-
mic injury (6-8). There is evidence for involvement of mul-
tiple caspases in hypoxic-ischemic brain injury. And caspase
inhibitors which were developed as antiapoptotic agents, are
believed to play a key role in the delayed neuronal cell death
observed after hypoxic-ischemic injury (7, 9).
The effects of growth hormone (GH) on the central ner-
vous system have become more apparent in the past decade.
Not only it is involved in brain growth and development,
but its qualities as a neuroprotective factor against injury are
now appreciated. Recent studies have demonstrated that GH
is involved in neuroprotection during hypoxic-ischemic brain
injury (10, 11). These protective roles are supported by the
ability of GH to accelerate glial cell division and myelino-
genesis, and GH is also thought to have neuroprotective roles
in neurogenesis (11). Although this neuroprotective mecha-
nism is not completely known, is probably achieved by inhi-
biting of caspase activities (12, 13).
The lipid peak in the 1H-MR spectrum has been reported
to be a marker for apoptosis during hypoxic-ischemic injury
(14). We have therefore used 1H-MRS to evaluate the effects
of GH as a caspase inhibitor on hypoxic-ischemic injury in
neonatal rat brains. 
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Neuroprotective Effects of Growth Hormone Against Hypoxic-Ischemic
Brain Injury in Neonatal Rats: 
1H Magnetic Resonance Spectroscopic
Study
Using 
1H-MRS, we evaluated the effects of growth hormone (GH) as a caspase
inhibitor on hypoxic-ischemic injury in neonatal rat brains. The right common carotid
arteries of rats were ligated, allowed to recover for 3 hr, and exposed to 8% oxygen
for 2 hr. GH was given just prior to HI insult and animals were divided into four groups:
control, intracerebroventricular (ICV), intracerebroventricular/intraperitoneal (ICV/IP),
and intraperitoneal (IP). Localized in vivo 
1H-MRS and TUNEL staining were per-
formed 24 hr after HI injury. Lipid/N-acetyl aspartate (NAA) and lipid/creatine (Cr)
ratios were used as apoptotic markers. Gross morphologic changes at 2 weeks
were used to evaluate the effects of GH. The lipid/NAA ratio was lower in the ICV
and ICV/IP groups than in the control, and the lipid/Cr ratio was lower in the ICV
group than in the control. The number of TUNEL positive cells was decreased in
the ICV and ICV/IP groups, and the degree of morphologic change indicative of
brain injury was lower in the ICV group and somewhat lower in the ICV/IP group.
The degree of morphologic change correlated with the lipid/NAA and lipid/Cr ratios.
These findings suggest that GH exerts neuroprotective effects in cerebral hypoxic-
ischemic injury.
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MATERIALS AND METHODS
Animals
The right common carotid arteries of 7-day old Sprague-
Dawley rats (mean weight=13.3 g) were ligated under ha-
lothane anesthesia. After a recovery period of 3 hr, they were
exposed to 8% oxygen at 37℃for about 120 min. GH (Eut-
rophin, LGPhD, Korea) was administered just prior to hypox-
ic-ischemic insult. The rats were divided into four groups:
control (10  L distilled water, n=29), intracerebroventricu-
lar (ICV, 10  L GH in 10  L distilled water, n=23), intrac-
erebroventricular/intraperitoneal (ICV+IP, n=21), and intra-
peritoneal (IP, 10 mg/kg GH in distilled water, n=23).
1H-MRS, TUNEL staining, and gross morphologic changes
Localized in vivo 1H-MRS was performed on a Bruker Bio-
spec 4.7T MRI/MRS System equipped with active shielded
gradients and ASPECT3000 computer with TOMIKON
hardware and software (Bruker, Fallanden, Switzerland). Spec-
tra were acquired in the right cerebral hemisphere of rats 24
hr after the onset of hypoxic-ischemic insult. Water suppressed
1H-MR spectra were acquired using a VOSY sequence with
detection of the double-refocused spin echo signal from the
selected voxel (3×2×2  L, 12  L) using the following acq-
uisition parameters: SW=5,000 Hz, SI=4,096 pts, NS=128,
TR/TE=3,000/30 and 135 msec. To identify the peak at 1.3
ppm, the spectra were acquired at echo times of 30 and 135
msec in order to differentiate the lactate peak from the lipid
peak. Peak areas were measured and the lipid/N-acetyl aspar-
tate (NAA) and lipid/creatine (Cr) ratios were used as apop-
totic markers.
After the 1H-MRS examinations on the 1st day, 6 brains
from each group were perfused with 0.9% saline solution
mixed with 2 units/mL of heparin, followed by perfusion
with 4% paraformaldehyde in PBS solution. Each brain was
isolated, and TUNEL staining was performed using an in
situ Cell Death Detection Kit, POD (Boehringer Mannheim,
Germany), as described. Apoptotic cells were counted 3 times
in the parietal area of the brain using a ×200 lens, and the
mean apoptotic cell numbers were calculated using Image
Analyzer software.
Gross morphologic changes were scored at 2 weeks using
a 5 point grading system as method by Palmer et al. (15),
where 0 indicates no change and 4 indicates the most severe
injury.
Statistical analysis
Data were expressed as mean±SD. Significance was asse-
ssed by unpaired t-test and ANOVA followed by Kruskall
Wallis test. Spearman correlation was used to investigate
relationships between lipid/NAA and lipid/Cr ratio and mor-
phologic score. A p-value of 0.05 indicated statistical signif-
icance. 
RESULTS
The lipid/NAA ratio was significantly lower in the ICV
(8.5±3.1) and ICV/IP (9.2±2.5) groups than in the con-
trol group (12.2±4.6); although the lipid/NAA ratio in the
IP group (11.4±3.7) was lower than in the control group,
this difference was not significant (Fig. 1). The lipid/Cr ratio
was also significantly lower in the ICV group (8.1±3.5) than
in the control group (10.9±4.4); the lipid/Cr ratio was lower
in the ICV/IP (9.2±3.4) and IP (9.6±3.5) groups than in
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Fig. 1. Lipid/NAA ratios among control and growth hormone pretre-
ated groups. *p<0.05 compared with control. 
NAA, N-acetyl aspartate; ICV, intracerebroventricular; IP, intraperi-
toneal. 
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Fig. 2. Lipid/Cr ratios among control and growth hormone pretreat-
ed groups. *p<0.05 compared with control. 
Cr, Creatine; ICV, intracerebroventricular; IP, intraperitoneal. 
*
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the control group, but these differences were not statistical-
ly significant (Fig. 2).
TUNEL staining was done on the 1st day. Although the
number of TUNEL positive cells did not differ between the
control and IP groups, there were fewer in the ICV and ICV/
IP groups (Fig. 3).
We scored gross morphologic changes at 2 weeks to eval-
uate the effects of GH. We found that the morphologic scores
were significantly lower in the ICV group (1.4±1.3) and
somewhat lower in the ICV/IP group (1.8±1.4) than in the
control group (2.2±1.4), but not in the IP group (2.2±1.2)
(Fig. 4). Furthermore, morphologic scores significantly cor-
related with the lipid/NAA and lipid/Cr ratios (Fig. 5).
DISCUSSION
Recently 1H-MRS has been used as a quantitative nonin-
vasive assessment tool in monitoring of brain development
and in the diagnosis of neurologically damaged infants (3-
5). 1H-MRS can detect metabolites such as NAA and other
acetyl compounds, which serve as primarily neuronal mark-
ers; Cr, including phosphocreatine and Cr, which are bioen-
ergetic markers; choline-containing compounds (Cho), which
are released during membrane disruption; and lactate (Lac),
which accumulates in response to anaerobic tissue metabolism
(2, 16). Decreased NAA/Cho and NAA/Cr ratio and increased
Cho/Cr ratio have were in asphyxiated neonates with poor
neurologic outcomes after 1 yr (4, 17). 1H-MRS in asphyxi-
ated neonates has also shown increased lactate and decreased
NAA in thalamus, as well as increased Lac and decreased Cr
in basal ganglia (18, 19). During hypoxic-ischemic injury,
there is a significant increase in the lipid peak, which corre-
lates with apoptotic cell death, as well as in the intensity of
the lipid peak, which is directly related to the apoptotic cell
Fig. 5. Correlations of Lipid/NAA (A) and Lipid/Cr (B) ratios with morphologic scores. NAA, N-acetyl aspartate; Cr, Creatine.
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Fig. 4. Morphologic scores among control and growth hormone
pretreated groups. *p<0.05 compared with control. 
ICV, intracerebroventricular; IP, intraperitoneal. 
*
Fig. 3. Hypoxic-ischemic injury in the right hemispheres of neona-
tal rat brains pretreated with growth hormone. There were many
apoptotic cells in the control and IP groups, but fewer in the ICV
and ICV+IP groups. ICV, intracerebroventricular; IP, intraperito-
neal. TUNEL stain (×100).
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count (14). We therefore used the lipid/NAA and lipid/Cr
ratios as apoptotic markers.
Newborn infants subjected to transient hypoxic-ischemic
injury during birth asphyxia are apparently relatively normal
soon after resuscitation but show evidence of delayed cere-
bral injury hours later, the magnitude of which predicts the
severity of later neurodevelopmental impairment (20,  21).
The mechanism of delayed injury is unclear, but apoptotic
cells are detected in brains of infants who died after birth
asphyxia, suggesting that inappropriate activation of the apop-
totic pathway accounts, at least in part, for the delayed cell
death (6, 8, 21).
Apoptosis was first described as a type of cell death distinct
from necrosis, with no swelling or loss of membrane integri-
ty, and no inflammatory response from the host tissue (22).
Apoptotic cells undergo a ubiquitous physiologic process
that is essential to the development and survival of multicel-
lular organisms. This process takes place during embryologic
development, turnover of gastrointestinal epithelium, and
the regulation of the immune system. Many pathological
events that cause necrosis, including hypoxic-ischemic injury,
can also induce apoptosis (2, 4, 6, 23). Necrosis may predo-
minate in more intense ischemic damage, whereas apoptosis
may occur during milder ischemic damage and may take
time to develop (24). Immature cortical neurons have been
shown to be more susceptible to apoptosis than mature neu-
rons, perhaps because cells of younger animals more readily
undergo apoptosis than cells of more mature animals (21,
25). Thus, blocking the apoptotic cascade may prolong the
therapeutic window after hypoxic-ischemic events, especial-
ly in the developing brain (6-8).
The ability of specific therapeutic agents to reduce neuro-
nal damage associated with hypoxic-ischemic injury has been
tested in animal models. Caspase inhibitors, which have anti-
apoptotic activity and are believed to play a key role in the
delayed neuronal cell death after hypoxic-ischemic injury (7,
9). Caspases are synthesized in most cells as inactive precur-
sors and are subsequently activated. Caspase-3 is a terminal
enzyme in the caspase family that activates an endonuclease
(caspase-activated DNAse), resulting in DNA fragmentation
(26). Caspase inhibitors, including inhibitors of caspase-3,
may prolong the therapeutic window after hypoxic-ischemic
injury (7, 27, 28).
Recently, GH administration has been reported to inhibit
neuronal death during hypoxic-ischemic injury, and to have
a neuroprotective effect in the cerebral cortex, hippocampus,
and thalamus (10, 11). Although the mechanism is not com-
pletely known, several reports suggest that hypoxic-ischemic
injury induces neuronal death by downregulating Bcl-2 pro-
tein levels, followed by sequential activation of the caspases,
and that GH protects neuronal cells by inhibiting alterations
in Bcl-2 protein levels and caspase activities (12, 13). 
We found that the lipid/NAA ratio was significantly lower
in rats administered GH by the ICV and ICV/IP routes, that
lipid/Cr ratio was significantly lower in rats administered
GH by the ICV, and that the degree of morphologic changes
in the brain was significantly correlated with the lipid/NAA
and lipid/Cr ratios. In our results, lipid/NAA ratio and lipid/
Cr ratio were not significantly changed by IP administration
of GH. Because GH does not usually cross the blood-brain
barrier, IP administration of GH may not block cell death.
Taken together, these findings suggest that GH exerts neu-
roprotective effects in cerebral hypoxic-ischemic injury by
inhibiting apoptosis, especially in the early stage after insult.
Our results also suggest that GH, as a caspase inhibitor, can
have therapeutic value in neuroprotective effect of hypoxic-
ischemic brain injury. 
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